New press release: A major discovery in triple-negative breast cancer thanks to innovative HCS Pharma’s technology

Lille, February 5, 2024HCS Pharma, a pioneering biotechnology company that enables the recreation of human organ avatars in vitro, announces that its BIOMIMESYS® technology has played a key role in the scientific discoveries of the teams led by Professor Robert-Alain Toillon from the University of Lille (CANTHER/ONCOLille) and Professor Caroline Read more…

GOODBYE 2023!

HCS Pharma wishes you an excellent year 2024 full of rebound, laughter, joy, and innovation! As the clocks mark the passage of time, a wave of optimism fills the minds. Technological advances, scientific discoveries and commitments to sustainability promise of a bright future. Communities come together to address global challenges, Read more…

New scientific article citing BIOMIMESYS® as powerful tool to study metastases of breast cancer

We are delighted to announce that a very interesting study using BIOMIMESYS® to study the metastasis of breast cancer has been published in Experimental Hematology & Oncology Journal (Impact factor 11,4). This article untitled “ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells” (Cicero, Read more…

New press release out: HCS Pharma participates in the development of an improved biomimetic liver model on chip for drug discovery

HCS Pharma announces the closure of the “MIMLIVERonChip” project, funded by the French National Research Agency (ANR, project ANR 19 CE19-0020) and coordinated by BMBI Biomechanics and Bioengineering joint research unit (UTC/ CNRS), headed by Dr Cécile Legallais, CNRS research director. This project led to the publication of Taha Messelmani’s Read more…